Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor

Abstract Background Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. Methods We u...

Full description

Bibliographic Details
Main Authors: Guoqiao Zheng, Kristina Sundquist, Jan Sundquist, Asta Försti, Akseli Hemminki, Kari Hemminki
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.3454
id doaj-e10d708d462749aabd8a2b7458fc7ad3
record_format Article
spelling doaj-e10d708d462749aabd8a2b7458fc7ad32020-11-25T03:36:30ZengWileyCancer Medicine2045-76342020-11-019218258826510.1002/cam4.3454Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factorGuoqiao Zheng0Kristina Sundquist1Jan Sundquist2Asta Försti3Akseli Hemminki4Kari Hemminki5Division of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg GermanyCenter for Primary Health Care Research Lund University Malmö SwedenCenter for Primary Health Care Research Lund University Malmö SwedenDivision of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg GermanyCancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki FinlandDivision of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg GermanyAbstract Background Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. Methods We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. Results Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. Conclusions Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.https://doi.org/10.1002/cam4.3454cancer riskimmune suppressionmultiple cancersrisk factors
collection DOAJ
language English
format Article
sources DOAJ
author Guoqiao Zheng
Kristina Sundquist
Jan Sundquist
Asta Försti
Akseli Hemminki
Kari Hemminki
spellingShingle Guoqiao Zheng
Kristina Sundquist
Jan Sundquist
Asta Försti
Akseli Hemminki
Kari Hemminki
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
Cancer Medicine
cancer risk
immune suppression
multiple cancers
risk factors
author_facet Guoqiao Zheng
Kristina Sundquist
Jan Sundquist
Asta Försti
Akseli Hemminki
Kari Hemminki
author_sort Guoqiao Zheng
title Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_short Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_full Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_fullStr Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_full_unstemmed Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_sort rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2020-11-01
description Abstract Background Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. Methods We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. Results Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. Conclusions Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.
topic cancer risk
immune suppression
multiple cancers
risk factors
url https://doi.org/10.1002/cam4.3454
work_keys_str_mv AT guoqiaozheng ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT kristinasundquist ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT jansundquist ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT astaforsti ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT akselihemminki ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT karihemminki ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
_version_ 1724549755493679104